ECSP045179A - Tibolona en el tratamiento de desórdenes asociados con la administración de fármacos que previenen la síntesis del estrógeno endógeno - Google Patents
Tibolona en el tratamiento de desórdenes asociados con la administración de fármacos que previenen la síntesis del estrógeno endógenoInfo
- Publication number
- ECSP045179A ECSP045179A EC2004005179A ECSP045179A ECSP045179A EC SP045179 A ECSP045179 A EC SP045179A EC 2004005179 A EC2004005179 A EC 2004005179A EC SP045179 A ECSP045179 A EC SP045179A EC SP045179 A ECSP045179 A EC SP045179A
- Authority
- EC
- Ecuador
- Prior art keywords
- estrogen
- disorders
- drugs
- treatment
- tibolone
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 title abstract 2
- 229960001023 tibolone Drugs 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 229940011871 estrogen Drugs 0.000 abstract 4
- 239000000262 estrogen Substances 0.000 abstract 4
- 210000000481 breast Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010030247 Oestrogen deficiency Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 229940046844 aromatase inhibitors Drugs 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un tratamiento para desórdenes relacionados con la deficiencia de estrógenos en mujeres que presentan dichos desórdenes mientras están bajo tratamiento con un fármaco que previene la síntesis del estrógeno endógeno. Dichos fármacos son, por ej., fármacos anti-cancerígenos tales como los inhibidores de la aromatasa. La invención radica en el uso de tibolona que presenta una acción beneficiosa inesperada en este grupo específico de pacientes, puesto que no estimula las mamas mientras que previene la pérdida de la masa ósea y alivia los desórdenes climatéricos, en un grupo de pacientes en el que esta situación es más complicada que en cualquier otro grupo, debido a la naturaleza del tratamiento concomitante del cáncer (la carencia de estrógeno circulante produce una mayor severidad en los desórdenes y la falta de efecto en el receptor de estrógeno aumenta el riesgo asociado con la estimulación estrogénica de las mamas una vez que se administran compuestos tipo estrógeno).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02075235 | 2002-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045179A true ECSP045179A (es) | 2004-08-27 |
Family
ID=27589110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005179A ECSP045179A (es) | 2002-01-22 | 2004-07-06 | Tibolona en el tratamiento de desórdenes asociados con la administración de fármacos que previenen la síntesis del estrógeno endógeno |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050124592A1 (es) |
| EP (1) | EP1469861A1 (es) |
| JP (1) | JP2005518412A (es) |
| KR (1) | KR20040073572A (es) |
| CN (1) | CN1620298A (es) |
| BR (1) | BR0306789A (es) |
| CA (1) | CA2472240A1 (es) |
| EC (1) | ECSP045179A (es) |
| HR (1) | HRP20040635A2 (es) |
| IL (1) | IL162769A0 (es) |
| IS (1) | IS7338A (es) |
| MX (1) | MXPA04007071A (es) |
| PL (1) | PL371181A1 (es) |
| RU (1) | RU2004125594A (es) |
| WO (1) | WO2003061665A1 (es) |
| ZA (1) | ZA200405262B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0302572D0 (en) | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE63051B1 (en) * | 1989-03-18 | 1995-03-22 | Akzo Nv | Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one |
| ZA941464B (en) * | 1993-03-05 | 1994-09-27 | Akzo Nv | Use of pregnane derivative |
| WO2000008001A1 (en) * | 1998-08-07 | 2000-02-17 | Chiron Corporation | Substituted isoxazole as estrogen receptor modulators |
-
2003
- 2003-01-16 KR KR10-2004-7011160A patent/KR20040073572A/ko not_active Withdrawn
- 2003-01-16 PL PL03371181A patent/PL371181A1/xx not_active Application Discontinuation
- 2003-01-16 MX MXPA04007071A patent/MXPA04007071A/es not_active Application Discontinuation
- 2003-01-16 EP EP20030731620 patent/EP1469861A1/en not_active Withdrawn
- 2003-01-16 CN CNA038025108A patent/CN1620298A/zh active Pending
- 2003-01-16 WO PCT/EP2003/000373 patent/WO2003061665A1/en not_active Ceased
- 2003-01-16 JP JP2003561609A patent/JP2005518412A/ja active Pending
- 2003-01-16 RU RU2004125594/14A patent/RU2004125594A/ru not_active Application Discontinuation
- 2003-01-16 US US10/502,444 patent/US20050124592A1/en not_active Abandoned
- 2003-01-16 IL IL16276903A patent/IL162769A0/xx unknown
- 2003-01-16 HR HR20040635A patent/HRP20040635A2/hr not_active Application Discontinuation
- 2003-01-16 CA CA002472240A patent/CA2472240A1/en not_active Abandoned
- 2003-01-16 BR BR0306789-0A patent/BR0306789A/pt not_active IP Right Cessation
-
2004
- 2004-06-28 IS IS7338A patent/IS7338A/is unknown
- 2004-07-01 ZA ZA2004/05262A patent/ZA200405262B/en unknown
- 2004-07-06 EC EC2004005179A patent/ECSP045179A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200405262B (en) | 2005-08-31 |
| IL162769A0 (en) | 2005-11-20 |
| IS7338A (is) | 2004-06-28 |
| HRP20040635A2 (en) | 2004-10-31 |
| CA2472240A1 (en) | 2003-07-31 |
| BR0306789A (pt) | 2004-12-28 |
| JP2005518412A (ja) | 2005-06-23 |
| KR20040073572A (ko) | 2004-08-19 |
| PL371181A1 (en) | 2005-06-13 |
| CN1620298A (zh) | 2005-05-25 |
| WO2003061665A1 (en) | 2003-07-31 |
| EP1469861A1 (en) | 2004-10-27 |
| US20050124592A1 (en) | 2005-06-09 |
| MXPA04007071A (es) | 2004-10-29 |
| RU2004125594A (ru) | 2005-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23096498A (es) | Restos de administración terapéutica novedosos y usos de estos | |
| AR068702A1 (es) | Composiciones farmaceuticas | |
| Magnowska et al. | Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy | |
| JP2020509024A5 (es) | ||
| Xue et al. | STAT3 inhibitor WP1066 as a novel therapeutic agent for bCCI neuropathic pain rats | |
| PH12021551023A1 (en) | Methods for shrinking pituitary tumors | |
| BRPI0416275A (pt) | métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada | |
| BR0316057A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| Vučković et al. | Synergistic interaction between ketamine and magnesium in lowering body temperature in rats | |
| Raju et al. | Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases | |
| Griffin et al. | Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy | |
| Bosco et al. | An integrated approach with homeopathic medicine and electro-acupuncture in anaesthesiology during breast cancer surgery | |
| AR048806A1 (es) | Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio | |
| Koltyn et al. | Changes in mood state following whole-body hyperthermia | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| WO2022046452A3 (en) | Nanoparticulate system for delivery of pain relief agents | |
| ES2272555T3 (es) | Composicion de estrogeno y otras hormonas con ascorbato, lisina, prol ina y otras sustancias. | |
| MX2022014923A (es) | Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos cyp2c9. | |
| Delfino et al. | Combination treatment in CTCL: the current role of bexarotene | |
| BR0306789A (pt) | Uso de tibolona e método de tratamento de queixas relacionadas com a deficiência do estrogênio em pacientes do sexo feminino | |
| BR112019013907A2 (pt) | combinação de um inibidor de mcl-1 e um composto de taxano, usos e composições farmacêuticas dos mesmos | |
| Re et al. | Correcting Misinformation about the Science and Practice of Evidence-Based, Safe and Effective Ozone Therapy | |
| Viscusi et al. | HTX-011, a proprietary, extended-release combination of bupivacaine and meloxicam, reduces acute postoperative pain intensity and opioid consumption after bunionectomy: results from an interim analysis | |
| MX2017013481A (es) | Composicion farmaceutica de liberacion sostenida que contiene rivastigmina. | |
| CY1120669T1 (el) | Συνδυαστικη θεραπεια για αγωγη σκληρυνσης κατα πλακας |